+ All Categories
Home > research cber center
A History of Stats at the FDA Mary A. Foulkes, Ph.D. U.S. Food And Drug Administration Office of Biostatistics and Epidemiology Center for Biologics Evaluation.
A History of Stats at the FDA Mary A. Foulkes, Ph.D. U.S. Food And Drug Administration Office of Biostatistics and Epidemiology Center for Biologics Evaluation.
218 views
Foi and iig
Foi and iig
649 views
21 cfr part 11 guidance for industry
21 cfr part 11 guidance for industry
2.783 views
Use of Outside Experts in FDAs Premarket Evaluation of Medical Devices Donna-Bea Tillman AU/OPM II AU/OPM II December 2004 An Action Learning Project Mans.
Use of Outside Experts in FDAs Premarket Evaluation of Medical Devices Donna-Bea Tillman AU/OPM II AU/OPM II December 2004 An Action Learning Project Mans.
215 views
1 GOOD MORNING! BONJOUR! GOEDEMORGEN!. 2 An Introduction to certain aspects of the US FDA Murray M. Lumpkin, MD Deputy Commissioner International Programs.
1 GOOD MORNING! BONJOUR! GOEDEMORGEN!. 2 An Introduction to certain aspects of the US FDA Murray M. Lumpkin, MD Deputy Commissioner International Programs.
217 views
Investigator-held IND Studies Jeffrey W. Clark, MD DF/HCC Medical Director for Clinical Trials Operations April 25, 2008.
Investigator-held IND Studies Jeffrey W. Clark, MD DF/HCC Medical Director for Clinical Trials Operations April 25, 2008.
216 views
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Roger D.
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Roger D.
213 views
An Interagency Model for Collaboration and Operation Interagency Portal for Science Education Meeting National Academies of Science March 18, 2009 Sharon.
An Interagency Model for Collaboration and Operation Interagency Portal for Science Education Meeting National Academies of Science March 18, 2009 Sharon.
217 views
© 2011 Smith Moore Leatherwood LLP. ALL RIGHTS RESERVED. Challenges in Clinical Research Trials Christee G. Laster Smith Moore Leatherwood LLP 1180 W.
© 2011 Smith Moore Leatherwood LLP. ALL RIGHTS RESERVED. Challenges in Clinical Research Trials Christee G. Laster Smith Moore Leatherwood LLP 1180 W.
220 views
Toxicology in Drug Development Lynnda Reid, Ph.D. Pharmacology/Toxicology Reviewer Center for Drug Evaluation and Research (CDER) Rafael Ponce, Ph.D.,
Toxicology in Drug Development Lynnda Reid, Ph.D. Pharmacology/Toxicology Reviewer Center for Drug Evaluation and Research (CDER) Rafael Ponce, Ph.D.,
232 views
FDA Considerations For Regulation Of Nanomaterial Containing Products Nakissa Sadrieh, Ph.D. Office of Pharmaceutical Science, CDER, FDA.
FDA Considerations For Regulation Of Nanomaterial Containing Products Nakissa Sadrieh, Ph.D. Office of Pharmaceutical Science, CDER, FDA.
219 views
FDA Regulatory Perspective: Data Integrity Steve Wilson, Dr.P.H., CAPT USPHS Deputy Director, Division of Biometrics II, CDER/FDA NIH Roadmap Program Feasibility.
FDA Regulatory Perspective: Data Integrity Steve Wilson, Dr.P.H., CAPT USPHS Deputy Director, Division of Biometrics II, CDER/FDA NIH Roadmap Program Feasibility.
225 views